PhoreMost Secures £33M in Series B Funding to Propel ‘Drugging the Undruggable’ Innovation
PhoreMost, the cutting-edge UK biopharmaceutical enterprise specializing in innovative drug development, has successfully closed an impressive £33 million Series B funding round. This latest round, which saw significant oversubscription, underscores the growing confidence in PhoreMost’s pioneering approach to addressing previously untargetable disease mechanisms. Central to PhoreMost’s strategy is their revolutionary SITESEEKER platform. This technology excels…